Skip to main content

A randomized phase II trial of bevacizumab (BV) plus oral everolimus (EV) versus bevacizumab alone for recurrent or persistent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal cancer (PPC).

Publication ,  Conference
Tew, WP; Sill, M; McMeekin, DS; Secord, AA; Bonebrake, AJ; Schilder, J; Stuckey, A; Rice, L; Tewari, KS; Aghajanian, C
Published in: Journal of Clinical Oncology
May 20, 2014

Duke Scholars

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2014

Volume

32

Issue

15_suppl

Start / End Page

5546 / 5546

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Tew, W. P., Sill, M., McMeekin, D. S., Secord, A. A., Bonebrake, A. J., Schilder, J., … Aghajanian, C. (2014). A randomized phase II trial of bevacizumab (BV) plus oral everolimus (EV) versus bevacizumab alone for recurrent or persistent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal cancer (PPC). In Journal of Clinical Oncology (Vol. 32, pp. 5546–5546). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2014.32.15_suppl.5546
Tew, William P., Michael Sill, D Scott McMeekin, Angeles Alvarez Secord, Albert J. Bonebrake, Jeanne Schilder, Ashley Stuckey, Laurel Rice, Krishnansu Sujata Tewari, and Carol Aghajanian. “A randomized phase II trial of bevacizumab (BV) plus oral everolimus (EV) versus bevacizumab alone for recurrent or persistent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal cancer (PPC).” In Journal of Clinical Oncology, 32:5546–5546. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.5546.
Tew WP, Sill M, McMeekin DS, Secord AA, Bonebrake AJ, Schilder J, et al. A randomized phase II trial of bevacizumab (BV) plus oral everolimus (EV) versus bevacizumab alone for recurrent or persistent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal cancer (PPC). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. 5546–5546.
Tew, William P., et al. “A randomized phase II trial of bevacizumab (BV) plus oral everolimus (EV) versus bevacizumab alone for recurrent or persistent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal cancer (PPC).Journal of Clinical Oncology, vol. 32, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2014, pp. 5546–5546. Crossref, doi:10.1200/jco.2014.32.15_suppl.5546.
Tew WP, Sill M, McMeekin DS, Secord AA, Bonebrake AJ, Schilder J, Stuckey A, Rice L, Tewari KS, Aghajanian C. A randomized phase II trial of bevacizumab (BV) plus oral everolimus (EV) versus bevacizumab alone for recurrent or persistent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal cancer (PPC). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. 5546–5546.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2014

Volume

32

Issue

15_suppl

Start / End Page

5546 / 5546

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences